(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug amycretin in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese.

The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said.

Amycretin, the Danish drugmaker's next generation obesity drug, has a dual mode action. Like its popular weight-loss drug Wegovy, amycretin mimics the gut hormone GLP-1, but it also mimics the effect of a hunger-suppressing pancreatic hormone called amylin.